Business Wire

MI-EATON

23.3.2022 11:32:06 CET | Business Wire | Press release

Share
Eaton Celebrates 50 Years of MLocker® Differential Production

Power management company Eaton today announced its Vehicle Group is celebrating 50 years of MLocker® differential production. The mechanical locking differential provides drivers with best-in-class traction without the need for pushbuttons, shift knobs, or other driver intervention, and is applicable to vehicles with both internal combustion engines and electrified vehicles (EVs).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220323005209/en/

“We’re happy to celebrate this important milestone for the MLocker differential, which is built on the success of its predecessor, our popular Posi differential,” said Mark Kramer, business unit director, Torque Control Products, Eaton’s Vehicle Group. “The unique design and proven quality of the MLocker differential have made it the differential of choice for global full-size pickups and sport-utility vehicles, and even a recently launched electrified urban truck in the Asia-Pacific region.”

Driving original equipment innovation

Utilizing a self-contained, automatic engagement mechanism, the MLocker differential engages in low-traction situations when a wheel speed difference (compared to the other rear wheel) of 100 revolutions per minute (RPM) or greater is detected. Automatic locking takes less than a fraction of a second, improving traction and providing the driver with increased safety and confidence when traveling on wet or icy roads, gravel, mud, and dirt. The MLocker differential is also compatible with existing anti-lock brake and vehicle stability systems, which simplifies OEM integration.

During normal driving conditions, the MLocker differential functions as a light-bias, limited-slip differential. When a low-traction situation occurs that causes a wheel speed difference, a flyweight mechanism opens to engage a latching bracket, triggering a self-energizing clutch system until both axles turn at the same speed (full lock), thereby preventing further wheel slip. Unlocking occurs automatically and the differential resumes normal operation.

The MLocker differential has undergone modifications over its long production run, but the foundational design and concept have remained constant.

“Functionally it’s the same design, but we have made a lot of improvements over the years. Our initial concept has weathered the test of time, although it’s been consistently improved to meet the needs of the industry,” said Keith E. Morgensai, an engineering specialist who has been involved in MLocker differential engineering and evolution for more than 40 years.

“It’s deceptively simple, but there is an awful lot of engineering that went into its development,” Morgensai said.

Since launching the MLocker differential, Eaton’s Vehicle Group has continued to add to its differentials portfolio that offers solutions for all user profiles.

Eaton’s complete line of differentials now includes:

  • Detroit Locker® differential – A fully automatic locking differential that provides ultimate traction for mild to extreme vehicle applications. It is uniquely engineered to keep both wheels in drive mode, even if one wheel lifts off the ground.
  • Detroit Truetrac® differential – A helical-gear performance limited-slip differential that maximizes wheel traction and enhances driving and handling characteristics.
  • ELocker® differential – A highly engineered unit that allows maximum driveline flexibility. Users can switch from a fully open to a fully locked axle at the touch of a button. The forged case and four-pinion gears provide added strength and capability.
  • InfiniTrac™ differential – An electronically controlled, limited-slip differential that provides optimized vehicle performance at any speed and traction condition.
  • Posi® differential – A limited-slip differential that automatically prevents wheel slip before it can start. It easily integrates into most axle designs and is tunable for application requirements.

Eaton also recently announced its Torque control systems business has launched an extensive lineup of specialized differentials for EVs with comparable performance to differentials for traditional internal combustion engine vehicles.

The passenger vehicle market is increasingly transitioning to EVs, and Eaton has the expertise and experience to provide the solution EV manufacturers need.

Eaton’s Traction Control family of differentials can provide improved traction in adverse conditions, such as snow and mud, and improved stability while trailering. As a global supplier, Eaton has extensive knowledge of vehicle dynamics and safety standards, as well as decades of experience working with global automotive manufacturers to integrate differentials into new vehicle platforms, including EVs. This technology is an example of how Eaton is progressing toward achieving its 2030 Sustainability Targets. By 2030, the company aims to reduce emissions from its solutions and throughout its value chain by 15%.

“Our years of experience producing industry-leading differentials allows us to provide our customers with a differential solution to meet their every need,” Kramer said. “The success of the MLocker differential was just the beginning of our journey to become a global supplier of differentials.”

Learn more about Eaton’s complete line of differentials .

Eaton is an intelligent power management company dedicated to improving the quality of life and protecting the environment for people everywhere. We are guided by our commitment to do business right, to operate sustainably and to help our customers manage power ─ today and well into the future. By capitalizing on the global growth trends of electrification and digitalization, we’re accelerating the planet’s transition to renewable energy, helping to solve the world’s most urgent power management challenges, and doing what’s best for our stakeholders and all of society.

Founded in 1911, Eaton has been listed on the NYSE for nearly a century. We reported revenues of $19.6 billion in 2021 and serve customers in more than 170 countries. For more information, visit www.eaton.com . Follow us on Twitter and LinkedIn .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye